Monitoring of the presence of EGFR-mutated DNA during EGFR-targeted therapy may assist in the prediction of treatment outcome

The aim of our trial was to evaluate the prognostic significance of qualitative ctDNA analysis on different stages of EGFR mutated non-small cell lung cancer (NSCLC) treatment.We included 99 patients amendable for the first line treatment with either gefitinib/erlotinib (n = 87), afatinib (n = 10) o...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: F.V. Moiseenko, N.M. Volkov, A.S. Zhabina, M.L. Stepanova, N.A. Rysev, V.V. Klimenko, A.V. Myslik, E.V. Artemieva, V.V. Egorenkov, N.H. Abduloeva, A.O. Ivantsov, E.S. Kuligina, E.N. Imyanitov, V.M. Moiseyenko
Format: Artigo
Langue:Inglês
Publié: Elsevier 2022-01-01
Collection:Cancer Treatment and Research Communications
Sujets:
NSCLC
EGFR
Targeted therapy
ctDNA
Prognosis
Accès en ligne:http://www.sciencedirect.com/science/article/pii/S2468294222000132
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires